Department of Rheumatology, Almazov Medical Research Centre, 197341 St. Petersburg, Russia.
Laboratory of Autoimmune Diagnostics, St. Petersburg Pavlov State Medical University, 197022 St. Petersburg, Russia.
J Immunol Res. 2014;2014:516593. doi: 10.1155/2014/516593. Epub 2014 May 4.
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are potent autoantigenic targets in systemic autoimmune rheumatic diseases (SARD). Loss of tolerance to the RA33 complex consisting of hnRNP A2 and its alternatively spliced variants B1 and B2 has been the interest of rheumatologists. A novel ELISA for the detection of anti-hnRNP B1 autoantibodies has been developed to investigate the prevalence thereof in 397 patients with SARD, including patients with rheumatoid arthritis (RA), spondyloarthropathy (SPA), juvenile chronic arthritis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and Sjögren's syndrome (SS), in comparison to 174 controls. Anti-hnRNP B1 autoantibodies were significantly more prevalent in patients with SARD than controls (47/397, 11.8% versus 2/174, 1.1%; P<0.001). In particular, anti-hnRNP B1 were found more frequently in the disease cohorts than in the controls and were present in 24/165 (14.5%) patients with RA, 6/58 (10.3%) SPA, 11/65 (16.9%) SSc, and 4/50 (8.0%) SLE. In RA patients, anti-hnRNP B1 autoantibodies correlated significantly with C-reactive protein levels and erythrocyte sedimentation rate, while in patients with SSc it was associated with features of arterial wall stiffness and presence of hypertension. Anti-hnRNP B1 autoantibodies occur in SARD and seem to be correlated with distinct clinical characteristics in patients with RA and SSc.
异质核核糖核蛋白 (hnRNPs) 是系统性自身免疫性风湿病 (SARD) 中的强效自身抗原靶标。对由 hnRNP A2 及其交替剪接变体 B1 和 B2 组成的 RA33 复合物的耐受性丧失一直是风湿病学家关注的焦点。已经开发出一种用于检测抗 hnRNP B1 自身抗体的新型 ELISA，以研究其在 397 例 SARD 患者（包括类风湿关节炎 (RA)、脊柱关节炎 (SPA)、幼年特发性关节炎、系统性红斑狼疮 (SLE)、系统性硬化症 (SSc) 和干燥综合征 (SS) 患者）中的患病率，并与 174 例对照进行比较。与对照组相比，SARD 患者中抗 hnRNP B1 自身抗体的患病率明显更高（47/397，11.8% 比 2/174，1.1%；P<0.001）。特别是，在疾病队列中发现抗 hnRNP B1 的频率高于对照组，并且在 24/165（14.5%）例 RA 患者、6/58（10.3%）例 SPA、11/65（16.9%）例 SSc 和 4/50（8.0%）例 SLE 患者中存在。在 RA 患者中，抗 hnRNP B1 自身抗体与 C 反应蛋白水平和红细胞沉降率显著相关，而在 SSc 患者中与动脉壁僵硬的特征和高血压的存在相关。抗 hnRNP B1 自身抗体发生在 SARD 中，似乎与 RA 和 SSc 患者的不同临床特征相关。
